The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
 
Eugene R Ahn
Employment - Cancer Treament Centers of America
Leadership - Cancer Treament Centers of America
 
Herbert Leon Duvivier
Speakers' Bureau - AstraZeneca; Guardant Health; Regeneron
 
Drew W. Rasco
Research Funding - 23andMe (Inst); Abbvie (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Cullinan Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Kronos; Merck (Inst); Molecular Templates; PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)
 
Agnes Rethy
Employment - Molecular Templates
 
Chris Moore
Employment - Molecular Templates
 
Amy Yuet
Employment - Molecular Templates
 
Sandra R. Hankins
Employment - Molecular Templates
 
Rachael Orlandella
Employment - Molecular Templates
 
Swati Khanna
Employment - Molecular Templates
 
Joseph Dekker
Employment - Molecular Templates
 
Angela Georgy
Employment - Molecular Templates
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curio Science (Inst); EMD Serono (Inst); Evidera (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intellisphere (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Molecular Templates (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis